Soleno Therapeutics, Inc. (NASDAQ:SLNO) is a biopharmaceutical company that focuses on developing treatments for rare diseases. Recently, Wells Fargo adjusted its grade for Soleno to "Overweight," while maintaining a "hold" action. The stock price at the time was $63.85, and Wells Fargo revised its price target from $123 to $106.
During Soleno's Q3 2025 earnings call, key figures like Anish Bhatnagar and Meredith Manning discussed the company's performance. The call included analysts from major financial institutions such as Goldman Sachs and TD Cowen. The discussion likely covered financial results and strategic initiatives, providing insights into Soleno's future outlook.
Soleno reported a net revenue of $66 million from VYKAT XR sales in Q3 2025, resulting in a positive net income of $26 million. Since VYKAT XR's approval in March 2025, Soleno has received 1,043 patient start forms, with 397 in the third quarter. The company has engaged 494 unique prescribers, including 199 in Q3, and has 764 active patients on the drug.
The stock, priced at $63.85, has seen a decrease of 2.74% today, with a change of $1.80. Trading has ranged from a low of $63.81 to a high of $67.43. Over the past year, SLNO reached a high of $90.32 and a low of $41.50. The company's market capitalization is approximately $3.39 billion, with a trading volume of 1,743,502 shares.
Soleno has also strengthened its leadership by appointing Mark W. Hahn to its Board of Directors and Audit Committee. This move is part of the company's efforts to enhance its strategic direction and governance. With over 132 million lives covered under its initiative, Soleno continues to expand its reach in the biopharmaceutical industry.
